Our Products
Our Products

MyDekla

MyDekla

Generic:

Daclatasvir 

 

Therapeutic Class:

Viral Hepatitis Products

 

Composition:

MyDekla 60mg = Each film-coated tablet contains daclatasvir dihydrochloride equivalent to 60mg daclatasvir

 

Description:

MyDekla use in combination with other medicinal products for the treatment of chronic hepatitis C virus (HCV) infection in adults

 

Indications

  • Hepatitis C genotype 1
  • Recurrent HCV infection post-liver transplant
  • Hepatitis C genotype 3
 

Dosage:

 

Genotype 1:

 

  • Without cirrhosis: MyDekla plus MyHep for 12 weeks
  • Compensated (Child-Pugh A) cirrhosis: MyDekla plus MyHep (sofosbuvir) for 12 weeks
  • Decompensated (Child-Pugh B or C) cirrhosis: MyDekla plus MyHep (sofosbuvir) plus ribavirin for 12 weeks
  • Posttransplant: MyDekla plus sofosbuvir MyHep (sofosbuvir) plus ribavirin for 12 weeks

 

Genotype 3:

 

  • Without cirrhosis: MyDekla plus MyHep (sofosbuvir) for 12 weeks
  • Compensated (Child-Pugh A) or decompensated (Child-Pugh B or C) cirrhosis: MyDekla plusMyHep (sofosbuvir) plus ribavirin for 12 weeks
  • Post transplant: MyDekla plus MyHep (sofosbuvir) plus ribavirin for 12 weeks
 

Presentation:

MyDekla 60 mg tab is available in pack of 28 tablets